12:00 AM
 | 
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Depakote ER divalproex regulatory update

After a post-marketing review of events from FDA's Adverse Events Reporting System (AERS), the agency identified 6 cases of developmental delay in the absence of teratogenicity associated with maternal use of Abbott's divalproex during pregnancy between 1983 and April 2009. Two of the cases occurred...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >